Stiripentol in Dravet Syndrome

NCT01533506 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2013-02-28

No results posted yet for this study

Summary

The patient has failed all other available agents and has intractable epilepsy due to Dravet Syndrome. Stiripentol is highly efficacious in Dravet Syndrome. The overall goals of therapy with Stiripentol are primarily to significantly reduce the frequency and severity of seizures.

Conditions

Interventions

DRUG

stiripentol

Stiripentol up to 30 mg/kg/day to control seizures

Sponsors & Collaborators

Principal Investigators

  • Elaine Wirrell, MD · Mayo Clinic

Eligibility

Min Age
11 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01533506 on ClinicalTrials.gov